Sunshine Biopharma
SBFM
1 hedge funds and large institutions have $341K invested in Sunshine Biopharma in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
1.86% less ownership
Funds ownership: 4.46% → 2.6% (-1.9%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $90K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
-$52K |
| 2 |
Dakota Wealth Management
Palm Beach Gardens,
Florida
|
-$22K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$9K |
| 4 |
Morgan Stanley
New York
|
-$7K |
SBFM Hedge Fund Activity: Q3 2022 in Review
1 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q3 2022, worth a combined $341K — down 57% from $800K a quarter earlier.
Fund positioning in SBFM was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Virtu Financial, cutting an estimated $52K.
- 1 institutional investor held Sunshine Biopharma (SBFM) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $341K of Sunshine Biopharma stock for Q3 2022, down 57% quarter-over-quarter.
- 0 funds opened new Sunshine Biopharma positions in Q3 2022 and 0 closed out.
- The largest Sunshine Biopharma seller in Q3 2022 was Virtu Financial, an estimated $52K sold.
Based on aggregated 13F filings for Q3 2022.